Powles T, et al. A phase II study investigating the safety and efficacy of savolitinib and durvalumab in metastatic papillary renal cancer (CALYPSO). ASCO-GU 2019, abstract 545.
Neoadjuvante immuuntherapiecombinatie inzetbaar en effectief bij blaaskanker
okt 2020 | Immuuntherapie, Uro-oncologie